A proteolytic fragment of histone deacetylase 4 protects the heart from failure by regulating the hexosamine biosynthetic pathway
Nature Medicine2017Vol. 24(1), pp. 62–72
Citations Over TimeTop 10% of 2017 papers
Lorenz Lehmann, Zegeye Hailu Jebessa, Michael M. Kreußer, Axel Horsch, Tao He, Mariya Kronlage, Matthias Dewenter, Viviana Sramek, Ulrike Oehl, Jutta Krebs-Haupenthal, Albert H von der Lieth, Andrea Schmidt, Qiang Sun, Julia Ritterhoff, Daniel Finke, Mirko Völkers, Andreas Jungmann, Sven W. Sauer, Christian T. Thiel, Alexander Nickel, Michael Kohlhaas, Michaela Schäfer, Carsten Sticht, Christoph Maack, Norbert Gretz, Michael Wagner, Ali El‐Armouche, Lars S. Maier, Juan E. Camacho Londoño, Benjamin Meder, Marc Freichel, Hermann‐Josef Gröne, Patrick Most, Oliver J. Müller, Stephan Herzig, Eileen E. M. Furlong, Hugo A. Katus, Johannes Backs
Related Papers
- → Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC–MEF2 complexes(2009)131 cited
- → Histone deacetylase inhibitor MS-275 stimulates bone formation in part by enhancing Dhx36-mediated TNAP transcription(2011)56 cited
- → Pyrrole‐Based Hydroxamates and 2‐Aminoanilides: Histone Deacetylase Inhibition and Cellular Activities(2009)10 cited
- → Design, synthesis and biological evaluation of novel histone deacetylase inhibitors based on virtual screening(2011)14 cited
- → Supplementary Figures 1-2 from Statins Increase p21 through Inhibition of Histone Deacetylase Activity and Release of Promoter-Associated HDAC1/2(2023)